Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Рандомизированное исследование III фазы: сравнительная оценка комбинации капецитабина и оксалиплатина (XELOX) с комбинацией 5-фторурацила/лейковорина/ оксалиплатина (FOLFOX) в качестве первой линии терапии метастатического колоректального рака
Рандомизированное исследование III фазы: сравнительная оценка комбинации капецитабина и оксалиплатина (XELOX) с комбинацией 5-фторурацила/лейковорина/ оксалиплатина (FOLFOX) в качестве первой линии терапии метастатического колоректального рака
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938–47.
2. Van Cutsem E, Twelves C, Cassidy J et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol 2001; 19: 4097–106.
3. Van Cutsem E, Hoff PM, Harper P et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: Integrated efficacy data and novel analyses from two large, randomized, phase III trials. Br J Cancer 2004; 90: 1190–7.
4. Hoff PM, Ansari R, Batist G et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 2001; 19: 2282–92.
5. Twelves C, Wong A, Nowacki MP et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352: 2696–704.
6. Cassidy J, Tabernero J, Twelves C et al. XELOX (capecitabine plus oxaliplatin): Active firstline therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004; 22: 2084–91.
7. Grothey A, Jordan K, Kellner O et al. Capecitabine plus irinotecan (CAPIRI) vs capecitabine plus oxaliplatin (CAPOX) as first-line therapy of advanced colorectal cancer (ACRC): Updated results of a randomized phase II trial. Eur J Cancer 2003; 1: S90 (suppl; abstr 295).
8. Scheithauer W, Kornek GV, Raderer M et al. Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2003; 21: 1307–12.
9. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335–42.
10. Saltz L, Clarke S, Diaz-Rubio E et al. Efficacy and safety of bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol doi:10.1200/JCO.2007.14.9930
11. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205–16.
12. Ducreux M, Bennouna J, Hebbar M et al. Efficacy and safety findings from a randomized phase III study of capecitabine (X) + oxaliplatin (O) (XELOX) vs. infusional 5- FU/LV + O (FOLFOX-6) for metastatic colorectal cancer (MCRC). J Clin Oncol 2007; 25: 170s (suppl; abstr 4029).
13. Porschen R, Arkenau H-T, Kubicka S et al. Capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin: A randomized comparison in metastatic colorectal cancer – a final report of the AIO Colorectal Study Group. J Clin Oncol 2007; 25: 4217–23.
14. Diaz-Rubio E, Tabernero J, Gomez-Espana A et al. Phase III study of capecitabine plus oxaliplatin versus continuous infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: Final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors trial. J Clin Oncol 2007; 25: 4224–30.
15. Rothenberg ML, Navarro M, Butts C et al. Phase III trial of capecitabine + oxaliplatin (XELOX) vs. 5-fluorouracil (5-FU), leucovorin (LV), and oxaliplatin (FOLFOX4) as 2nd-line treatment for patients with metastatic colorectal cancer (MCRC). J Clin Oncol 2007; 25: 171s (abstr 4031).
2. Van Cutsem E, Twelves C, Cassidy J et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol 2001; 19: 4097–106.
3. Van Cutsem E, Hoff PM, Harper P et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: Integrated efficacy data and novel analyses from two large, randomized, phase III trials. Br J Cancer 2004; 90: 1190–7.
4. Hoff PM, Ansari R, Batist G et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 2001; 19: 2282–92.
5. Twelves C, Wong A, Nowacki MP et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352: 2696–704.
6. Cassidy J, Tabernero J, Twelves C et al. XELOX (capecitabine plus oxaliplatin): Active firstline therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004; 22: 2084–91.
7. Grothey A, Jordan K, Kellner O et al. Capecitabine plus irinotecan (CAPIRI) vs capecitabine plus oxaliplatin (CAPOX) as first-line therapy of advanced colorectal cancer (ACRC): Updated results of a randomized phase II trial. Eur J Cancer 2003; 1: S90 (suppl; abstr 295).
8. Scheithauer W, Kornek GV, Raderer M et al. Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2003; 21: 1307–12.
9. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335–42.
10. Saltz L, Clarke S, Diaz-Rubio E et al. Efficacy and safety of bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol doi:10.1200/JCO.2007.14.9930
11. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205–16.
12. Ducreux M, Bennouna J, Hebbar M et al. Efficacy and safety findings from a randomized phase III study of capecitabine (X) + oxaliplatin (O) (XELOX) vs. infusional 5- FU/LV + O (FOLFOX-6) for metastatic colorectal cancer (MCRC). J Clin Oncol 2007; 25: 170s (suppl; abstr 4029).
13. Porschen R, Arkenau H-T, Kubicka S et al. Capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin: A randomized comparison in metastatic colorectal cancer – a final report of the AIO Colorectal Study Group. J Clin Oncol 2007; 25: 4217–23.
14. Diaz-Rubio E, Tabernero J, Gomez-Espana A et al. Phase III study of capecitabine plus oxaliplatin versus continuous infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: Final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors trial. J Clin Oncol 2007; 25: 4224–30.
15. Rothenberg ML, Navarro M, Butts C et al. Phase III trial of capecitabine + oxaliplatin (XELOX) vs. 5-fluorouracil (5-FU), leucovorin (LV), and oxaliplatin (FOLFOX4) as 2nd-line treatment for patients with metastatic colorectal cancer (MCRC). J Clin Oncol 2007; 25: 171s (abstr 4031).
Авторы
________________________________________________
J Clin Oncol 2008; 26 (12): 2006–12
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.